Physician profile
Mark Stradling
NPI 1982874509
$3,147.18
in general payments reported to CMS, 2019-2025
25 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $714 · 2021: $518 · 2022: $714 · 2023: $709 · 2024: $143 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947 · Entertainment: $13.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.21 |
| Entertainment | $13.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $512.39 | 2019-2022 | |
| Alcon Vision LLC | $398.05 | 2021-2024 | Clareon, Hydrus Microstent |
| Glaukos Corporation | $343.24 | 2020-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Sight Sciences, INC. | $239.37 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $209.01 | 2019-2021 | |
| Abbvie INC. | $178.03 | 2022-2024 | Durysta, Lumigan, Alphagan P |
| Ivantis, INC | $174.64 | 2020-2021 | |
| Microsurgical Technology, INC. | $160.06 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $131.72 | 2023 | Quatera 700 |
| Sun Pharmaceutical Industries INC. | $115.98 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $110.55 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Scoutpro Osmolarity System |
| Johnson & Johnson Surgical Vision, INC. | $86.13 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $83.81 | 2020-2021 | |
| Amgen INC. | $72.65 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $67.74 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $51.39 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $45.29 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $39.24 | 2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $23.86 | 2023 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $22.79 | 2023 | Tyrvaya |
| Shire North American Group INC | $21.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.47 | 2020 | |
| Eyepoint US, INC. | $15.87 | 2020 | |
| Optos, INC. | $13.37 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Eyevance Pharmaceuticals LLC | $13.00 | 2023 | Tobradex St |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stradling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.